NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$26.05

+1.31 (+5.30 %)

(As of 06/24/2021 01:51 PM ET)

Add

Compare

Today's Range

$25.17

▼

$26.49

50-Day Range

$16.33

▼

$33.07

52-Week Range

$15.88

▼

$54.21

Volume154,542 shs

Average Volume2.75 million shs

Market Capitalization$3.98 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.82

30 days | 90 days | 365 days | Advanced Chart

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Inflation hasn't dented earnings forecasts: Morning Brief
June 21, 2021 | finance.yahoo.com

Should You Buy This Cathie Wood Biotech Stock?
June 17, 2021 | finance.yahoo.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down to $23.68
June 16, 2021 | americanbankingnews.com

Brokerages Anticipate Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to Post -$0.52 Earnings Per Share
June 13, 2021 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.1%
June 11, 2021 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 4.3%
June 10, 2021 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Outperform at JMP Securities
June 10, 2021 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up to $17.92
June 7, 2021 | americanbankingnews.com

BRIEF-Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel In Advanced Melanoma At ASCO 2021 Annual Meeting
June 6, 2021 | msn.com

Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)
May 24, 2021 | markets.businessinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
Previous Symbol
CUSIPN/A
CIK1425205
Webwww.iovance.com
Phone(650) 260-7120
Employees241
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.48 per share
Price / Book5.81

Profitability

EPS (Most Recent Fiscal Year)($1.88)
Net Income$-259,580,000.00
Net MarginsN/A
Return on Equity-38.27%
Return on Assets-34.04%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares152,849,000
Market Cap$3.98 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.52 out of 5 stars

Medical Sector

547th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

83rd out of 198 stocks

4.4 Analyst's Opinion

Consensus Rating
Iovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.00, Iovance Biotherapeutics has a forecasted upside of 55.8% from its current price of $26.31.
Amount of Analyst Coverage
Iovance Biotherapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.2 Community Rank

Outperform Votes
Iovance Biotherapeutics has received 517 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Iovance Biotherapeutics has received 286 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Iovance Biotherapeutics has received 64.38% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote “Outperform” if you believe IOVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Iovance Biotherapeutics does not currently pay a dividend.
Dividend Growth
Iovance Biotherapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.70% of the stock of Iovance Biotherapeutics is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Iovance Biotherapeutics are expected to decrease in the coming year, from ($2.07) to ($2.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iovance Biotherapeutics is -14.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iovance Biotherapeutics is -14.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Iovance Biotherapeutics has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

Is Iovance Biotherapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Iovance Biotherapeutics stock.
View analyst ratings for Iovance Biotherapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) released its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.03.
View Iovance Biotherapeutics' earnings history.

How has Iovance Biotherapeutics' stock price been impacted by COVID-19?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have decreased by 12.3% and is now trading at $25.94.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for IOVA?

13 Wall Street analysts have issued 12 month target prices for Iovance Biotherapeutics' stock. Their forecasts range from $18.00 to $55.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:

Dr. Frederick G. Vogt Ph.D., Esq., Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 47, Pay $515.4k)
Mr. Jean-Marc Bellemin M.B.A., Chief Financial Officer & Principal Accounting Officer (Age 49, Pay $580k)
Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 54, Pay $551.4k)
Dr. Igor P. Bilinsky, Chief Operating Officer (Age 48)
Ms. Sara Pellegrino, VP of Investor Relations & PR
Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 61)
James Ziegler, Sr. VP of Commercial
Dr. Elma S. Hawkins, Advisor to the Board (Age 64)

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX) and Beam Therapeutics (BEAM).
View all of IOVA's competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.91%), Franklin Resources Inc. (5.90%), BlackRock Inc. (5.90%), Perceptive Advisors LLC (5.66%), Nikko Asset Management Americas Inc. (3.51%) and Sumitomo Mitsui Trust Holdings Inc. (3.61%).
View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Victory Capital Management Inc., Sei Investments Co., WCM Investment Management LLC, and Allianz Asset Management GmbH.
View insider buying and selling activity for Iovance Biotherapeutics or view top insider-selling stocks.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Credit Suisse AG, Goldman Sachs Group Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., JPMorgan Chase & Co., and Morgan Stanley.
View insider buying and selling activity for Iovance Biotherapeutics or or view top insider-buying stocks.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $25.94.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics has a market capitalization of $3.96 billion. The biotechnology company earns $-259,580,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

Iovance Biotherapeutics employs 241 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

Where are Iovance Biotherapeutics' headquarters?

Iovance Biotherapeutics is headquartered at 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at (650) 260-7120 or via email at [email protected]

This page was last updated on 6/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here